Maggie is a senior editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.
She has a BA in English from Penn State University. You can connect with Maggie on LinkedIn.
Addressing the Hidden Burden of Polycythemia Vera: Andrew Kuykendall, MD
Noting the profound impact of living with a chronic condition that constantly reminds patients of their "patient" status, Andrew Kuykendall, MD, Moffitt Cancer Center, emphasizes the importance of therapies that can offer a sense of normalcy.
Navigating Insurance Hurdles and Policy Shortfalls in Breast Cancer Care: Anasuya Gunturi, MD, PhD
At the recent regional Institute for Value-Based Medicine® event in Boston, Anasuya Gunturi, MD, PhD, Lowell General Hospital, was a panelist for the discussion, “Evolving Breast Cancer Care: Addressing Unmet Needs Across the Patient Journey.”
The Evolving Landscape of Myasthenia Gravis Therapies: A Q&A With Miriam Freimer, MD
Miriam Freimer, MD, clinical professor of neurology at The Ohio State University Wexner Medical Center, reflects on how findings from the RAISE-XT trial potentially translate to real-world practice and looks to the future of treatment for the autoimmune neuromuscular disorder.
Primary Care Doctors Lead Rising Physician Exodus From Medicare
According to the American Medical Association, blame for the ongoing physician shortage may lie with overly burdensome administrative processes, an antiquated Medicare payment system, and lack of education for residents in primary care and psychiatry.
FDA Delivers a CRL to Glofitamab for Relapsed/Refractory DLBCL
The FDA determined the data from STARGLO did not provide sufficient evidence to support approving glofitamab-gxbm (Columvi) in combination with gemcitabine and oxaliplatin to treat relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Best of Managed Care Cast: Top 5 Episodes From the First Half of 2025
These interviews are the top episodes, by listens, from among the 21 podcast episodes The American Journal of Managed Care® produced over the first half of 2025. Give them all another listen, and perhaps learn something new.
Lung Transplant Referrals Lag for High-Risk Patients With PAH
Despite recommendations on early referral for lung transplantation in cases of pulmonary arterial hypertension (PAH), there is a lack of in-depth understanding of this current landscape; in this analysis, clinical parameter data were used to compare outcomes between patients who were and were not referred for lung transplantation.
AI Meets Medicare: Inside CMS’ WISeR Model With Sanjay Doddamani, MD, MBA
Sanjay Doddamani, MD, MBA, a former senior advisor to the Center for Medicare and Medicaid Innovation, and internist and cardiologist by training, explains how the Wasteful and Inappropriate Service Reduction (WISeR) Model hopes to work, and addresses concerns about delays and denials from revamped prior authorization processes.
Dupilumab Shows Strong Efficacy in SCORAD-Based AD Assessment
With few real-life studies that have specifically focused on how atopic dermatitis (AD) affects patients living with the chronic inflammatory skin condition in Latin American countries, the present authors investigated dupilumab-related outcomes among 100 patients using SCORing Atopic Dermatitis (SCORAD) index values.
Insurance Gaps Threaten Cancer Treatment Success
Access to and affordability of immune checkpoint inhibitors, which can be lifesaving if patients receive them on time and under optimal circumstances, continue to top the list of reasons behind outcomes disparities for patients who have private insurance vs those who remain uninsured.
Understanding How Complement C5 Inhibitors Work in MG: Miriam Freimer, MD
In myasthenia gravis, complement plays a big role in what happens to the muscle end of the neuromuscular junction, explains Miriam Freimer, MD, an author on 5 abstracts presented at the recent 15th MGFA International Conference on Myasthenia and Related Disorders.
Atrasentan Has Promising Long-Term Potential in IgA Nephropathy: Richard Lafayette, MD, FACP
Richard Lafayette, MD, FACP, explains why a REMS program is not required for the endothelin A receptor antagonist and how patients may need to adjust should final ALIGN trial data fail to show a clinical benefit of atrasentan.
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
From Red Tape to Relief: Rewriting the Rules of Prior Authorization
Up to 257 million Americans could benefit from these prior authorization reforms that could have cross-market implications on health care plans administered through commercial insurers, Medicare Advantage, and Medicaid.